skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

もっと見る

Resources

もっと見る

もっと見る

Products

もっと見る

もっと見る

17 Total results for product and free and sample content found

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

From US To EU: Young Biotechs Going It Alone

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

Topic Market Access Rare Diseases Strategy

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Alnylam Seeking Lumasiran Approvals Soon, But Has Two Rivals On Its Heels

Phase III results support early 2020 filings for what could be the RNAi specialist’s third commercial product, but two competing drugs for primary hyperoxaluria from Dicerna and OxThera aren’t far behind. 

Topic clinical-trials Launches rare-disease

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

How To Get Orphan Drug Status In Great Britain From 2021

Pink Sheet Brexit Orphan Drug Status

Updated guidance from the UK regulator, the MHRA, outlines the rules on orphan drug applications, criteria and exclusivity periods that will apply in Great Britain after the end of the Brexit transition period

Topic Pharma-Brexit Rare Diseases

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

US FDA's Regulatory Flexibility To Be Tested As Delcath Overhauls Melphalan Trial Design

US FDA's Regulatory Flexibility To Be Tested As Delcath Overhauls Melphalan Trial Design

Accrual difficulties force changes that nullify Special Protocol Assessment; ongoing, randomized FOCUS trial in patients with ocular melanoma that has metastasized to liver will become single-arm study and target enrollment will be reduced by 66%.

Topic Clinical trials Drug approval Rare Disease FDA

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Pharma Wants Clarity On Joint Evaluation Of EU Paediatric And Orphan Regulations

Pharma Wants Clarity On Joint Evaluation Of EU Paediatric And Orphan Regulations

The European Commission's plans to evaluate the EU pediatric and orphan drugs regulation in tandem.

Topic rare-disease

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Biosimilars in Inflammatory and Autoimmune Disease

Biosimilars Development in Autoimmune and Inflammatory Diseases webinar

Topic biosimilars rare-disease

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity

Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity

With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy

Topic rare-disease

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Future of Regenerative Medicine

Future of Regenerative Medicine

Find out about the past, present and future of regenerative medicine. 

Topic cancer rare-disease

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。

Eメール:inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。